Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low utilization of cancer genetics referrals in newly diagnosed Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTehilla BranderMRMichelle RudshteynMKMarina Kremyanskaya

Discussion

Loading...

Member takes

Overview

Retrospective study shows low cancer genetics referral rates in AML, indicating need for improved awareness.

Key Points

  • The aim is to determine the rate of cancer genetics referrals in newly diagnosed AML patients and identify gaps in care.
  • Single-center retrospective review of newly diagnosed de novo AML patients from 2015 to 2022.
  • Exclusion of patients with prior history of MDS or myeloproliferative neoplasms.
  • Assessment of NGS results and referral appropriateness based on NCCN criteria.
  • Out of 363 patients, 38.3% met criteria for genetic referral, but only 6.6% were referred.
  • Nine patients were referred for genetics, with four confirmed to have germline mutations.
  • Common referral criteria included age <50 years and prior malignancy.

Cite This Study

Brander et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd4ahttps://doi.org/10.1182/blood-2025-1085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia2024 · 2 citations
  2. 2Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute2025
  3. 3Implementing a Genetic Counselor-Led Model for Hereditary Myeloid Malignancies: A Real-World Study.2025
  4. 4Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults2025
  5. 5Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?2025 · 1 citations